MR4 sustained for 12 months is associated with stable deep molecular responses in chronic myeloid leukemia

Autor: Simone Claudiani, Aoife Gatenby, Richard Szydlo, George Nesr, Adi Shacham Abulafia, Renuka Palanicawandar, Georgios Nteliopoulos, Jamshid Khorashad, Letizia Foroni, Jane F. Apperley, Dragana Milojkovic

Publikováno v: Haematologica, Vol 104, Iss 11 (2019)

The majority of patients with newly diagnosed chronic myeloid leukemia (CML) will enjoy a life expectancy equivalent to that of unaffected individuals, but will remain on life-long treatment with a concomitant requirement for on-going hospital intera

Externí odkaz: https://doaj.org/article/4281796b92be4de481b0716400102984

E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy

Autor: Simone Claudiani, Jane F. Apperley, Robert Peter Gale, Richard Clark, Richard Szydlo, Simona Deplano, Renuka Palanicawandar, Jamshid Khorashad, Letizia Foroni, Dragana Milojkovic

Publikováno v: Haematologica, Vol 102, Iss 8 (2017)

Externí odkaz: https://doaj.org/article/0607ab1dfc7144b0b2195d2ff87c0942

Higher-order connections between stereotyped subsets

Autor: Andrea Patriarca, Marco Montillo, Niki Stavroyianni, Claudia Haferlach, Lesley-Ann Sutton, Livio Trentin, Franco Fais, Raphael Sandaltzopoulos, Arnon P. Kater, Anton W. Langerak, Marine Armand, Davide Rossi, Diane F. Jelinek, Davide Bagnara, Lydia Scarfò, Andreas Agathangelidis, Krzysztof Giannopoulos, Eugen Tausch, Andrey Sudarikov, Silvio Veronese, Salem H. Alshemmari, B V Biderman, Zadie Davis, Chrysoula Belessi, Lisa Bonello, Achilles Anagnostopoulos, Gerlinde Mitterbauer-Hohendanner, David Oscier, Sofia Kossida, Lone Bredo Pedersen, Paolo Ghia, Csaba Bödör, Christian Brieghel, Andrea Visentin, Véronique Giudicelli, Matthias Ritgen, Panagiotis Panagiotidis, Panagiotis Baliakas, Stephan Stilgenbauer, Ellen J van Gastel, Renee C. Tschumper, Christiane Pott, Frederic Davi, Katerina Gemenetzi, Valentina Guido, Elias Campo, Gianluca Gaidano, Irina Panovska, Sabine Jeromin, Karla Plevová, Kostas Stamatopoulos, Kamila Brázdilová, Maria Karypidou, Alba Navarro, Christof W. Schneider, Theodoros Moysiadis, Larry Mansouri, Darko Antic, Cristina Tresoldi, Constance Baer, Šárka Pospíšilová, Maria Roumelioti, Katrina Vanura, Xiao-Jie Yan, Hana Skuhrová Francová, Richard Rosenquist, Blanca Espinet, Paola Francia di Celle, Monica Facco, Paul Costeas, Michael Hallek, Carsten Utoft Niemann, Teodora Karan-Djurasevic, Manja Meggendorfer, Kirsten Fischer, Aleksandar Dimovski, Letizia Foroni, Marie-Paule Lefranc, Mark Catherwood, Anne de Septenville, Anastasia Chatzidimitriou, Sarah Lawless, Nicholas Chiorazzi

Publikováno v: ERIC, the European Research Initiative on CLL 2021, ' Higher-order connections between stereotyped subsets : implications for improved patient classification in CLL ', Blood, vol. 137, no. 10, pp. 1365-1376 . https://doi.org/10.1182/blood.2020007039
Blood, 137(10), 1365-1376. American Society of Hematology
Blood

Chronic lymphocytic leukemia (CLL) is characterized by the existence of subsets of patients with (quasi)identical, stereotyped B-cell receptor (BcR) immunoglobulins. Patients in certain major stereotyped subsets often display remarkably consistent cl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::345d10461f72781148bcaddc188ba32d
http://www.scopus.com/inward/record.url?scp=85102607193&partnerID=8YFLogxK

Digital Droplet (dd) Polymerase Chain Reaction (PCR) Assays Offer Limited Advantages over Conventional Reverse-Transcriptase Quantitative PCR (RT-qPCR) for the Prediction of Molecular Recurrence after Treatment Discontinuation in Chronic Myeloid Leukemia (CML): Results from the Destiny Study

Autor: Kathy Dominy, Matthew Salmon, Richard Szydlo, Chloe Hayden, Helen E White, Mary Alikian, Dragana Milojkovic, Mhairi Copland, Letizia Foroni, Nicholas C.P. Cross, Richard E Clark, Jane F. Apperley

Publikováno v: Blood. 140:9631-9632

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::550a9a5f0bd1ba78353be9235efa219c
https://doi.org/10.1182/blood-2022-170375

A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease

Autor: Annie Latif, Arunima Mukhopadhyay, Mhairi Copland, Fiona Thomson, Dragana Milojkovic, Letizia Foroni, G. M. Smith, Jenny Byrne, Gillian A. Horne, Paolo Gallipoli, Philippe Schafhausen, Judith Dixon-Hughes, Franck E. Nicolini, P. Cony-Makhoul, Richard E. Clark, Wenjuan Cong, Gudmundur Vignir Helgason, Jon Stobo, Steffen Koschmieder, T H Brümmendorf, Lynn McMahon, Caroline Kelly, Tessa L. Holyoake

Publikováno v: Leukemia
LEUKEMIA
Horne, G, Stobo, J, Kelly, C, Mukhopadhyay, A, Latif, A, Dixon, J, McMahon, L, Cony-Makhoul, P, Byrne, J, Smith, G, Koschmieder, S, BrÜmmendorf, T, Schafhausen, P, Gallipoli, P, Thomson, F, Cong, W, Clark, R, Milojkovic, D, Helgason, V, Foroni, L, NICOLINI, F-E, Holyoake, T & Copland, M 2020, ' A randomised Phase II trial of Hydroxychloroquine and Imatinib versus Imatinib alone for patients with Chronic Myeloid Leukaemia in Major Cytogenetic Response with residual disease ', Leukemia . https://doi.org/10.1038/s41375-019-0700-9

1 In chronic-phase chronic myeloid leukaemia (CP-CML), residual BCR-ABL1+ leukaemia stem cells are 2 responsible for disease persistence despite TKI. Based on in vitro data, CHOICES (CHlorOquine and 3 Imatinib Combination to Eliminate Stem cells) was

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24af8c15119e8a2c9bc14fffc509365b
http://europepmc.org/articles/PMC7224085